Ongoing and emerging cyber-risks to legacy operational technology systems in bio/pharmaceutical manufacturing must be addressed.
As bio/pharma manufacturers make their operations and networks increasingly streamlined and interconnected, there is a need to connect older facilities to the supply chain. In turn, this means that operational technology (OT) cybersecurity measures must be introduced to legacy systems to support archaic equipment, older operating systems, and decades-old protocols as well as networks where it is not possible to fully monitor the operational network or to detect and control intrusions.
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 28–30
When referring to this article, please cite it as R. Brokamp and A. Karisik, “Tackling Cybersecurity Challenges in Legacy Systems," BioPharm International Regulatory Sourcebook (October 2020).
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.